FrancophonIA/ELRC3.0 huggingface dataset:
English: Puregon 900 IU/1.08 mL solution for injection EU/1/96/008/041
Maltese: NUMRU TAL-AWTORIZZAZZJONI GĦAT-TQEGĦID FIS-SUQ EU/1/96/008/041
English: A daily increase of oestradiol levels of 40-100% is considered to be optimal.
Maltese: estradjol b' 40-100% hija kkonsidrata li hi l-aħjar.
English: If a GnRH agonist (a medicine used to prevent early ovulation) has been given, higher doses of Puregon may be needed.
Maltese: Jekk jingħata agonista ta' GnRH (mediċina li tintuża biex tippreveni ovulazzjoni bikrija), jista' ikun hemm bżonn dożi aktar għolja ta' Puregon.
English: CARTRIDGE TEXT Puregon 300 IU/0.36 mL
Maltese: Ż-ŻGĦAR EWLENIN KITBA LI TIDHER FUQ L-ISKARTOĊĊ Puregon 300 IU/0.
English: Puregon 100 IU/0.5 mL solution for injection: Each vial contains the active substance follitropin beta, a hormone known as follicle-stimulating hormone (FSH), in a strength of 100 IU in 0.5 mL aqueous solution per vial.
Maltese: Kull kunjett fih is-sustanza attiva follitropin beta, ormon magħruf bħala ormon li jistimula l-follikuli (FSH), f'qawwa ta' 100 IU f'0.5 mL ta' soluzzjoni akweja f'kull kunjett.
English: Puregon 600 IU/0.72 mL solution for injection EU/1/96/008/039
Maltese: NUMRU TAL-AWTORIZZAZZJONI GĦAT-TQEGĦID FIS-SUQ EU/1/96/008/039
English: Puregon 150 IU/0.5 mL solution for injection follitropin beta
Maltese: Puregon 150 IU/0.5 mL injezzjoni follitropin beta IM/SC
English: Puregon 225 IU/0.5 mL solution for injection: Each vial contains the active substance follitropin beta, a hormone known as follicle-stimulating hormone (FSH), in a strength of 225 IU in 0.5 mL aqueous solution per vial.
Maltese: DIKJARAZZJONI TAS-SUSTANZA(I) ATTIVA(I) Kunjett wieħed fih 0.5 mL follitropin beta li jikkorrispondu għal: atività ta' 225
English: What Puregon contains
Maltese: Puregon 600
English: Puregon 600 IU/0.72 mL injection follitropin beta
Maltese: 72 mL soluzzjoni għall-injezzjoni follitropin beta
English: It is supplied in a glass vial.
Maltese: IU Puregon kuljum.
English: In males
Maltese: Akne
English: When given into a muscle the injection should be given by the doctor or nurse.
Maltese: L-ewwel injezzjoni ta' Puregon għandha tingħata biss fi preżenza ta' tabib jew infermiera.
English: Depending on the ovarian response, the following measurements can be considered to reduce OHSS: - withhold further stimulation with a gonadotropin for a maximum of 3 days (coasting); - withhold hCG and cancel the treatment cycle; - administer a dose lower than 10,000 IU of urinary hCG for triggering final oocyte maturation, e.g. 5,000 IU urinary hCG or 250 micrograms rec-hCG (which is equivalent to approximately 6,500 IU of urinary hCG); - cancel the fresh embryo transfer and cryopreserve embryos; - avoid administration of hCG for luteal phase support.
Maltese: OHSS jista' jiġi kkawżat mill-għoti ta' Chorionic Gonadotropin uman (hCG - human Chorionic Gonadotropin) u mit-tqala (hCG endoġenu). OHSS bikri normalment iseħħ fi żmien 10 ijiem wara lgħoti ta' hCG u jista' jkun assoċjat ma' rispons eċċessiv tal-ovarji għal stimulazzjoni minn gonadotropin. OHSS li jittardja jseħħ iktar minn 10 ijiem wara l-għoti ta' hCG, bħala konsegwenza tal-tibdiliet fl-ormoni bit-tqala.
English: - administer a dose lower than 10,000 IU of urinary hCG for triggering final oocyte maturation, e.g. 5,000 IU urinary hCG or 250 micrograms rec-hCG (which is equivalent to approximately 6,500 IU of urinary hCG); - cancel the fresh embryo transfer and cryopreserve embryos; - avoid administration of hCG for luteal phase support.
Maltese: IU hCG tal-awrina jew 250 mikrogramma ta' rec-hCG (li huma ekwivalenti għal madwar 6,500
English: Further information on Rasilez HCT can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
Maltese: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
English: Rasilez HCT received a marketing authorisation valid throughout the EU on 16 January 2009.
Maltese: Rasilez HCT irċieva awtorizzazzjoni għat-tqegħid fis-suq valida fl-EU kollha fis-16 ta' Jannar 2009.
English: Rasilez HCT can only be obtained with a prescription and it is available as tablets (150 mg/12.5 mg; 150 mg/25 mg; 300 mg /12.5 mg; 300 mg/25 mg).The recommended dose of Rasilez HCT is one tablet per day.
Maltese: Rasilez HCT jista' jinkiseb biss b'riċetta ta' tabib u jiġi bħala pilloli (150 mg/12.5 mg; 150 mg/25 mg; 300 mg /12.5 mg; 300 mg/25 mg).
English: Aliskiren on its own has been authorised in the EU since August 2007 as Rasilez, Sprimeo and Riprazo.
Maltese: L-aliskiren meħuda weħidha ilha awtorizzata fl-UE minn Awwissu 2007 bħala Rasilez, Sprimeo u Riprazo.
English: Other information about Rasilez HCT
Maltese: Informazzjoni oħra dwar Rasilez HCT
English: The studies compared the combination of aliskiren and hydrochlorothiazide with placebo (a dummy treatment), with aliskiren or hydrochlorothiazide taken alone, or with other medicines for hypertension (valsartan, irbesartan, lisinopril or amlodipine).
Maltese: L-istudji qabblu t-taħlita tal-aliskiren u lidroklorotijażid ma' plaċebo (kura finta), mal-aliskiren jew mal-idroklorotijażid meħudin waħedhom, jew ma' mediċini oħra kontra l-ipertensjoni (valsartan, irbesartan, lisinopril jew amlodipina).
English: The medicine contains the active substances aliskiren and hydrochlorothiazide.
Maltese: Il-mediċina fiha s-sustanzi attivi aliskiren u idroklorotijażid.
English: It blocks the activity of a human enzyme called renin, which is involved in the production of a substance called angiotensin I in the body.
Maltese: Din timblokka l-attività ta' enzima umana msejħa renina, li hija involuta fil-produzzjoni ta' sustanza msejħa anġjotensina I fil-ġisem.
English: As for all medicines, data on the use of Rasilez HCT are continuously monitored.
Maltese: Bħal għall-mediċini kollha, id-data dwar l-użu ta' Rasilez HCT hija ssorveljata kontinwament.
English: Angiotensin I is converted into the hormone angiotensin II, which is a powerful vasoconstrictor (a substance that narrows blood vessels).
Maltese: L-anġjotensina I tiġi konvertita flormon anġjotensina II, li huwa vażokostrittur qawwi (sustanza li ddejjaq il-vażi).
English: The most common side effect with Rasilez HCT (which may affect between 1 and 10 patients in 100) is diarrhoea.
Maltese: L-effett sekondarju l-aktar komuni b'Rasilez HCT (li jista' jaffettwa bejn pazjent 1 u 10 minn kull 100) huwa dijarea.
English: How is Rasilez HCT used?
Maltese: Kif jaħdem Rasilez HCT?
English: Rasilez HCT in combination with an ‘angiotensin converting enzyme (ACE) inhibitors' or ‘angiotensin receptor blockers' (ARBs) must not be used in patients with diabetes,
Maltese: Rasilez HCT f'taħlita ma' ‘inibituri tal enzima li tikkonverti l-anġjotensina (ACE)' jew ‘imblokkaturi tar-riċettur tal-anġjotensina' (ARBs) m'għandux jintuża f'pazjenti bid-dijabete, jew bi problemi renali moderati jew gravi.
English: What are the risks associated with Rasilez HCT?
Maltese: X'inhuma r-riskji assoċjati ma' Rasilez HCT?
English: The company presented information used in the assessment of aliskiren and from the published literature to support its application for Rasilez HCT, as well as information from additional studies.
Maltese: Il-kumpanija ppreżentat informazzjoni użata fil-valutazzjoni tal-aliskiren u middokumentazzjoni ppubblikata b'appoġġ għall-applikazzjoni tagħha għal Rasilez HCT, kif ukoll informazzjoni minn studji addizzjonali.
English: Other common side effects (which may affect more than 1 in 10 patients) that have been observed with hydrochlorothiazide alone are hypokalaemia (low blood potassium levels) and increases in blood cholesterol and triglyceride (a type of fat) levels.
Maltese: Effetti sekondarji komuni oħrajn (li jistgħu jaffettwaw aktar minn pazjent 1 minn kull 10) li ġew osservati bl-idroklorotijażid waħedha huma ipokalemija (livelli ta' potassju fid-demm baxxi) u żiediet fil-livelli ta' kolesterol u ta' trigliċeridi (tip ta' xaħam) fid-demm.
English: Overall, the company presented the results of nine main studies involving a total of almost 9,000 patients with essential hypertension.
Maltese: B'kollox, il-kumpanija ppreżentat ir-riżultati ta' disa' studji ewlenin li involvew total ta' kważi 9,000 pazjent b'ipertensjoni essenzjali.
English: Three additional studies showed that the active substances were absorbed in the body in the same way when taken as separate tablets and as Rasilez HCT.
Maltese: Tliet studji addizzjonali wrew li s-sustanzi attivi ġew assorbiti fil-ġisem bl-istess mod bħal meta ttieħdu bħala pilloli separati u bħala Rasilez HCT.
English: Rasilez HCT must not be used in patients who have had angioedema (swelling under the skin) with aliskiren, hereditary angioedema or angioedema of no obvious cause, who have anuria (a condition in which a patient cannot make or pass urine), severe kidney or liver impairment, or whose blood potassium levels are too low or blood calcium levels are too high.
Maltese: Rasilez HCT m'għandux jintuża f'pazjenti li kellhom anġjoedema (nefħa taħt il-ġilda) bl-aliskiren, anġjoedema ereditarja jew anġjoedema b'ebda kawża evidenti, li għandhom anurija (kondizzjoni li fiha l-pazjent ma jkunx jista' jagħmel jew jgħaddi l-urina), problemi gravi renali jew fil-fwied, jew li jkollhom livelli ta' potassju fid-demm baxxi wisq jew livelli tal-kalċju fid-demm għoljin wisq.
English: It must not be taken with ciclosporin, itraconazole or other medicines known as ‘potent P-glycoprotein inhibitors' (such as quinidine).
Maltese: M'għandux jittieħed maċ-ċiklosporina, l-itrakonażol jew mediċini oħra magħrufa bħala ‘inibituri qawwija talglikoproteina-P' (bħal quinidine).
English: Rasilez HCT is a medicine used to treat essential hypertension (high blood pressure) in adults.
Maltese: Rasilez HCT huwa mediċina li tintuża biex tikkura l-ipertensjoni essenzjali (pressjoni tad-demm għolja) fl-adulti.
English: Rasilez HCT (aliskiren / hydrochlorothiazide)
Maltese: Ħarsa ġenerali lejn Rasilez HCT u għalfejn huwa awtorizzat fl-UE
English: The medicine has been shown to reduce blood pressure more than each active substance alone.
Maltese: Il-mediċina ntweriet li tnaqqas il-pressjoni tad-demm aktar minn kull waħda mis-sustanzi attivi waħidha.
English: Most studies involved patients with mild to moderate hypertension and one involved patients with severe hypertension.
Maltese: Il-biċċa l-kbira tal-istudji involvew pazjenti b'ipertensjoni ħafifa sa moderata, u wieħed involva pazjenti b'ipertensjoni severa.
English: Side effects are similar to those of the two active substances.
Maltese: L-effetti sekondarji huma simili għal dawk taż-żewġ sustanzi attivi.
English: By lowering blood pressure, the risk caused by high blood pressure, such as having a stroke, is reduced.
Maltese: Bit-tnaqqis tal-pressjoni tad-demm, jitnaqqas ir-riskju kkawżat minn pressjoni tad-demm għolja, bħall-puplesija.
English: The two active substances in Rasilez HCT, aliskiren and hydrochlorothiazide, work in different ways to reduce blood pressure.
Maltese: Iż-żewġ sustanzi attivi f'Rasilez HCT, l-aliskiren u l-idroklorotijażid, jaħdmu b'modi differenti biex inaqqsu l-pressjoni tad-demm.
English: It is available as capsules (290 micrograms).
Maltese: Jiġi bħala kapsuli (290 mikrogramma).
English: The full EPAR for Constella can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Maltese: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: EPAR summary for the public linaclotide
Maltese: Sommarju tal-EPAR għall-pubbliku linaclotide
English: Other information about Constella
Maltese: Informazzjoni oħra dwar Constella
English: Constella is a medicine that contains the active substance linaclotide.
Maltese: Constella huwa mediċina li fiha s-sustanza attiva linaclotide.
English: This summary was last updated in November 2012.
Maltese: Is-sommarju ġie aġġornat l-aħħar fi Novembru 2012.
English: This is a summary of the European public assessment report (EPAR) for Constella.
Maltese: Dan huwa sommarju tar-Rapport Pubbliku Ewropew ta' Valutazzjoni (EPAR) għal Constella.
English: The European Commission granted a marketing authorisation valid throughout the European Union for Constella on 26 November 2012.
Maltese: Il-Kummissjoni Ewropea tat awtorizzazzjoni għat-tqegħid fis-suq valida fl-Unjoni Ewropea kollha għal Constella fis-26 ta' Novembru 2012.
English: Constella was investigated in two main studies involving a total of 1,608 patients with IBS with constipation, where it was compared with placebo (a dummy treatment).
Maltese: Constella kien investigat f'żewġ studji ewlenin li kienu jinvolvu total ta' 1,608 pazjenti b'IBS bi stitikezza, fejn tqabbel ma' plaċebo (kura finta).
English: Constella is used to treat the symptoms of moderate to severe irritable bowel syndrome (IBS) with constipation in adults.
Maltese: Constella jintuża għall-kura tas-sintomi tas-sindromu tal-musrana irritabbli (irritable bowel syndromeIBS) moderat sa sever bi stitikezza fl-adulti.
English: Similar results were obtained in the second study, with 54% of Constella patients experiencing an improvement in their pain and discomfort and 39% of them feeling considerably or completely relieved from symptoms for at least 6 out of the 12 weeks of treatment, compared with 39% and 17% of patients in the placebo group, respectively.
Maltese: Riżultati simili nkisbu fit-tieni studju, b'54% tal-pazjenti li ngħataw Constella jkollhom titjib fl-uġigħ u liskonfort tagħhom u 39% minnhom iħossuhom konsiderevolment jew kompletament ħielsa mis-sintomi għal mill-inqas 6 mit-12-il ġimgħa ta' kura, meta mqabbla ma' 39% u 17% tal-pazjenti fil-grupp talplaċebo, rispettivament.
English: In rare and more severe cases, diarrhoea may lead to dehydration, hypokalaemia (low blood potassium levels), decrease in blood bicarbonate, dizziness and orthostatic hypotension (low blood pressure on standing up).
Maltese: F'każijiet rari u aktar severi, id-dijarea tista' twassal għal deidrazzjoni, ipokalimja (livelli baxxi ta' potassju fid-demm), tnaqqis tal-bikarbonat fid-demm, sturdament u pressjoni baxxa ortostatika (pressjoni baxxa tad-demm meta wieħed iqum bil-wieqfa).
English: What is Constella?
Maltese: X'inhu Constella?
English: The active substance in Constella, linaclotide, attaches to some receptors in the gut called guanylate cyclase C. By attaching to these receptors, it reduces pain and increases the secretion of fluid into the gut, thereby loosening the stools and increasing bowel movements.
Maltese: Is-sustanza attiva f'Constella, linaclotide, taqbad ma' ċerti riċetturi fil-musrana msejħa guanylate cyclase C.
English: The most common side effect with Constella is diarrhoea, mainly mild to moderate, occurring in between 10 and 20 patients in 100.
Maltese: L-effett sekondarju l-aktar komuni b'Constella huwa d-dijarea, l-aktar ħafifa sa moderata, li sseħħ f'madwar 10 sa 20 pazjent f'100.
English: The effects of Constella were first tested in experimental models before being studied in humans.
Maltese: L-effetti ta' Constella ġew l-ewwel analizzati fuq mudelli sperimentali qabel ma ġew studjati filbniedem.
English: In the first study, 55% of patients who received Constella experienced a 30% or higher improvement in their pain and discomfort for at least 6 out of the 12 weeks of treatment, compared with 42% of patients who received placebo.
Maltese: Fl-ewwel studju, 55% tal-pazjenti li ngħataw Constella kellhom titjib ta' 30% jew aktar fl-uġigħ u l-iskonfort tagħhom għal mill-inqas 6 mit-12-il ġimgħa ta' kura, meta mqabbla ma' 42% tal-pazjenti li ngħataw il-plaċebo.
English: How has Constella been studied?
Maltese: Kif ġie studjat Constella?
English: In addition, 37% of patients who received Constella were considerably or completely relieved from symptoms for at least 6 out of the 12 weeks of treatment, compared with 19% of patients who received placebo.
Maltese: Barra minn hekk, 37% tal-pazjenti li ngħataw Constella kienu konsiderevolment jew kompletament ħielsa mis-sintomi għal mill-inqas 6 mit-12-il ġimgħa ta' kura, meta mqabbla ma' 19% tal-pazjenti li ngħataw plaċebo.
English: The CHMP noted that Constella has been shown to have clinically relevant, beneficial effects in patients with IBS with constipation in the long term (for up to six months).
Maltese: Is-CHMP innota li Constella ntwera li għandu effetti benefiċi klinikament rilevanti f'pazjenti bl-IBS u bi stitikezza fit-tul (sa sitt xhur).
English: The results after 26 weeks of treatment showed an improvement in pain (for at least 13 weeks out of the 26 weeks) in 54% of patients taking Constella compared with 36% of patients taking placebo, as well as relief from symptoms for at least 13 weeks in 37% of Constella patients, compared with 17% of patients in the placebo group.
Maltese: Ir-riżultati wara 26 ġimgħa ta' kura wrew titjib fl-uġigħ (għal mill-inqas 13-il ġimgħa minn 26 ġimgħa) f'54% tal-pazjenti li ħadu Constella meta mqabbla ma' 36% tal-pazjenti li ħadu plaċebo, kif ukoll serħan mis-sintomi għal mill-inqas 13-il ġimgħa f'37% tal-pazjenti li ħadu Constella, meta mqabbla ma' 17% tal-pazjenti fil-grupp tal-plaċebo.
English: One of the studies also looked at the effects of Constella following 26 weeks of treatment.
Maltese: Wieħed mill-istudji ħares ukoll lejn l-effetti ta' Constella wara 26 ġimgħa ta' kura.
English: Why has Constella been approved?
Maltese: Għaliex ġie approvat Constella?
English: Constella was shown to be more effective than placebo at improving the symptoms of IBS.
Maltese: Constella ntwera li huwa aktar effettiv mill-plaċebo fit-titjib tas-sintomi tal-IBS.
English: How does Constella work?
Maltese: Liema benefiċċju wera Constella waqt l-istudji mwettqa?
English: The recommended dose of Constella is one capsule once a day, taken at least 30 minutes before a meal.
Maltese: Id-doża rrakkomandata ta' Constella hija kapsula waħda darba kuljum, li tittieħed mill-inqas 30 minuta qabel l-ikel.
English: What is the risk associated with Constella?
Maltese: Għal xiex jintuża Constella?
English: Regarding safety, the CHMP concluded that the side effects with Constella, mainly diarrhoea, are manageable.
Maltese: Rigward is-sigurtà, is-CHMP ikkonkluda li l-effetti sekondarji b'Constella, l-aktar id-dijarea, huma ġestibbli.
English: IBS is a long-term disorder of the gut characterised by pain or discomfort in the abdomen and bloating together with altered bowel habit.
Maltese: L-IBS huwa disturb fit-tul tal-musrana kkaratterizzat minn uġigħ jew skonfort fl-addome u nefħa flimkien ma' tibdil fir-regolarità tal-musrana.
English: Further information on Melosus can be found on the Agency's website: ema.europa.eu/medicines/veterinary/EPAR/melosus.
Maltese: Aktar informazzjoni dwar Melosus tinstab fuq is-sit elettroniku tal-Aġenzija: ema.europa.eu/medicines/veterinary/EPAR/melosus.
English: Melosus (meloxicam)1
Maltese: Melosus (melossikam)
English: Other information about Melosus
Maltese: Informazzjoni oħra dwar Melosus
English: Melosus is available as an oral (taken by mouth) suspension as 0.5 mg/ml for use in cats and guinea pigs and 1.5 mg/ml for use in dogs.
Maltese: Melosus jiġi bħala sospensjoni orali (meħuda mill-ħalq) ta' 0.5 mg/ml għall-użu fil-qtates u fil-fniek talindi u ta' 1.5 mg/ml għall-użu fil-klieb.
English: Melosus received a marketing authorisation valid throughout the EU on21 February 2011.
Maltese: Melosus irċieva awtorizzazzjoni għat-tqegħid fis-suq valida fl-UE kollha fil-21 ta' Frar 2011.
English: Melosus contains meloxicam, which belongs to a class of medicines called non-steroidal antiinflammatory drugs (NSAIDs).
Maltese: Melosus fih il-melossikam, li tagħmel parti minn klassi ta' mediċini msejħa mediċini antiinfjammatorji nonsterojdali (NSAIDs).
English: Melosus contains the active substance meloxicam and is a ‘generic medicine'.
Maltese: Melosus fih is-sustanza attiva melossikam u huwa mediċina ġenerika.
English: Studies on the benefits and risks of the active substance in the authorised uses have already been carried out with the reference medicine, Metacam, and do not need to be repeated for Melosus.
Maltese: Diġà saru studji dwar il-benefiċċji u r-riskji tas-sustanza attiva fl-użijiet awtorizzati bil-mediċina ta' referenza, Metacam, u ma għandhomx għalfejn jiġu ripetuti għal Melosus.
English: What are the benefits and risks of Melosus?
Maltese: X'inhuma l-benefiċċji u r-riskji ta' Melosus?
English: As prostaglandins trigger inflammation, pain, exudation (fluid that leaks out of blood vessels during an inflammation) and fever, meloxicam reduces these signs of inflammation.
Maltese: Peress li l-prostaglandini jiskattaw l-infjamazzjoni, l-uġigħ, it-tnixxija (fluwidu li joħroġ mill-vażi waqt infjamazzjoni) u d-deni, il-melossikam tnaqqas dawn issinjali tal-marda.
English: Because Melosus is a generic medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine's.
Maltese: Minħabba li Melosus huwa mediċina ġenerika u bijoekwivalenti għall-mediċina ta' referenza, ilbenefiċċji u r-riskji tiegħu huma meqjusa li huma l-istess bħal dawk tal-mediċina ta' referenza.
English: In dogs, Melosus is used to lessen inflammation and pain in musculo-skeletal disorders.
Maltese: Fil-klieb, Melosus jintuża biex inaqqas l-infjammazzjoni u l-uġigħ f'disturbi muskoluskeletali.
English: In cats, Melosus is used to reduce pain and inflammation after orthopaedic and minor soft tissue surgery.
Maltese: Fil-qtates, Melosus jintuża biex inaqqas l-uġigħ u l-infjammazzjoni wara kirurġija ortopedika u kirurġija fuq it-tessut artab.
English: Guinea pigs
Maltese: Fniek tal-Indi
English: Why is Melosus authorised in the EU?
Maltese: Għalfejn Melosus huwa awtorizzat fl-UE?
English: Previously known as Melocam.
Maltese: Kif jintuża Melosus?
English: This means that Melosus contains the same active substance and works in the same way as a ‘reference medicine' already authorised in the European Union (EU) called Metacam.
Maltese: Dan ifisser li Melosus fih l-istess sustanza attiva u jaħdem bl-istess mod bħal “mediċina ta' referenza” diġà awtorizzata fl-Unjoni Europea (UE) msejħa Metacam.
English: The European Medicines Agency concluded that, in accordance with EU requirements, Melosus has been shown to have comparable quality and to be bioequivalent to Metacam.
Maltese: L-Aġenzija Ewropea għall-Mediċini kkonkludiet li, b'mod konformi mar-rekwiżiti tal-UE, Melosus wera li għandu kwalità komparabbli u huwa bijoekwivalenti għal Metacam.
English: The precautions are the same as for the reference medicine since Melosus is a generic medicine.
Maltese: Il-prekawzjonijiet huma bħal dawk tal-mediċina ta' referenza minħabba li Melosus huwa mediċina ġenerika.
English: How has Melosus been studied?
Maltese: Kif ġie studjat Melosus?
English: Moreover, it is used to lessen pain and inflammation in chronic musculo-skeletal disorders.
Maltese: Barra minn hekk, jintuża wkoll biex inaqqas l-uġigħ u l-infjammazzjoni f'disturbi muskoluskeletali kroniċi.
English: Melosus is an anti-inflammatory medicine used in dogs, cats and guinea pigs.
Maltese: Melosus huwa mediċina antiinfjammatorja li tintuża fil-klieb, fil-qtates u fil-fniek tal-Indi.
English: In guinea pigs Melosus is used to reduce pain after soft tissue surgery such as castration.
Maltese: Fil-fniek tal-Indi, Melosus jintuża biex inaqqas l-uġigħ wara kirurġija fuq it-tessut artab bħal kastrazzjoni.
English: How does Melosus work?
Maltese: Kif jaħdem Melosus?
English: What is Plendil?
Maltese: X'inhu Plendil?
English: Austria, Belgium, Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, Netherlands, Poland, Portugal, Romania, Slovakia, Spain, Sweden and United Kingdom, as well as in Iceland and Norway.
Maltese: Plendil u ismijiet assoċjati bħalissa qegħdin fis-suq fl-Istati Membri tal-UE li ġejjin: l-Awstrija, il-Belġju, il-Bulgarija, il-Kroazja, Ċipru, ir-Repubblika Ċeka, id-Danimarka, l-Estonja, il-Finlandja, Franza, ilĠermanja, il-Greċja. l-Ungerija, l-Irlanda, l-Italja, il-Latvja, il-Litwanja, il-Lussemburgu, Malta, il-Pajjiżi Baxxi, il-Polonja, il-Portugall, ir-Rumanija, l-Islovakkja, Spanja, l-Isvezja u r-Renju Unit, kif ukoll flIslanda u n-Norveġja.